An Alzheimer's drug developed by Eli Lilly slowed cognitive and functional decline for people with early stages of the disease, a study that could lead to a new commercially available drug for the ...

A sign for Eli Lilly & Co. sits outside their corporate headquarters in Indianapolis on April 26, 2017. The company said Wednesday, May 3, 2023, that its experimental Alzheimer's drug appeared to ...

Eli Lilly (NYSE:LLY) recently received FDA approval for a new dosing schedule of Kisunla, aimed at reducing amyloid-related ...

The benefit-risk balance is tipping more in favor of Eli Lilly’s Kisunla in early Alzheimer’s disease as the FDA ...

Eli Lilly and Company (LLY) announced on Wednesday that the U.S. Food and Drug Administration (FDA) has approved a label ...

Eli Lilly and Company (NYSE: LLY) is one of Goldman Sachs’ top healthcare stock picks. On July 9, the company confirmed the ...

Alzheimer’s patient brain scans, provided by Eli Lilly. The US company has reported full findings of its phase 3 clinical study of donanemab.

Eli Lilly said Wednesday its experimental Alzheimer's drug appeared to slow worsening of the mind-robbing disease in a large study, sending its stock up by 5% on investor optimism about the results.

The FDA will allow a new dosing schedule for Eli Lilly’s Alzheimer’s drug Kisunla that could lessen a known side effect of ...

Drugmaker Eli Lilly says that approval of its experimental Alzheimer’s medication donanemab will be delayed beyond the end of March as the US Food and Drug Administration plans to call a last ...

FDA delays Alzheimer’s drug for further review in surprise move. Eli Lilly had expected donanemab to be approved this month, but regulators will hold an advisory committee meeting to scrutinize ...